Search

Your search keyword '"Cioffi, M."' showing total 5 results
Start Over Author "Cioffi, M." Journal european journal of endocrinology
5 results on '"Cioffi, M."'

4. The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism

Author

Gherardo Mazziotti, Concetta Tuccillo, Nicola Caporaso, Carlo Carella, Francesca Sorvillo, Filomena Morisco, Giovanni Amato, Michele Cioffi, Mario Rotondi, Carella, C, Mazziotti, G, Morisco, Filomena, Rotondi, M, Cioffi, M, Tuccillo, C, Sorvillo, F, Caporaso, Nicola, Amato, G., Morisco, F, Cioffi, Michele, and Caporaso, N

Subjects
Adult, Male, Risk, medicine.medical_specialty, Thyroid Hormones, Endocrinology, Diabetes and Metabolism, Hepatitis C virus, Thyroid Gland, Alpha interferon, medicine.disease_cause, Antiviral Agents, Thyroiditis, Group B, chemistry.chemical_compound, Endocrinology, Hypothyroidism, Internal medicine, Ribavirin, medicine, Humans, Longitudinal Studies, Interferon alfa, Aged, Autoantibodies, Retrospective Studies, business.industry, Thyroid, Interferon-alpha, General Medicine, Hepatitis C, Chronic, Middle Aged, medicine.disease, Anti-thyroid autoantibodies, medicine.anatomical_structure, Cross-Sectional Studies, chemistry, Case-Control Studies, Drug Therapy, Combination, Female, business, medicine.drug
Abstract

OBJECTIVE: The aim of this study was to investigate whether the addition of ribavirin (RIBA) to interferon-alpha (IFN-alpha) therapy increases the risk of developing thyroid autoimmunity and/or dysfunction. DESIGN AND METHODS: The study group (group A) included 72 patients undergoing treatment with IFN-alpha (3-6 million units three times weekly) plus RIBA (1.0-1.2 g/day) for chronic hepatitis C (CHC), as first line therapy (30 cases) or as a second therapeutic attempt after a previous ineffective IFN-alpha treatment (42 cases). The control group (group B) encompassed 75 age- and sex-matched patients affected by CHC, undergoing treatment with IFN-alpha alone as first line therapy (35 cases) or as a second therapeutic attempt (40 cases). Thyroid autoimmunity and function were retrospectively evaluated on frozen aliquots, drawn before, after 6 months, and at the end of the antiviral treatment. In patients receiving two antiviral treatments (42 cases in group A and 40 cases in group B) thyroid parameters were also assayed on serum samples drawn before and at the end of the first IFN-alpha therapy. RESULTS: Thyroid autoimmunity rate (17/72 for group A and 17/75 for group B) as well as anti-thyroglobulin antibodies (TgAb) and anti-thyroid peroxidase antibodies (TPOAb) serum levels were comparable between the two groups. Similarly, in patients undergoing two consecutive antiviral treatments (42 cases in group A and 40 cases in group B) the percentage of positivity for thyroid autoantibodies did not change significantly from the first to the second therapeutic schedules in both groups, with no significant increase of median TgAb and TPOAb levels. By the same token, all but one patient negative for thyroid autoantibodies at the end of the first treatment remained so also during the subsequent treatment. In group A patients, the rate of hypothyroidism (11/72) was significantly higher than that observed in group B (3/75). Similarly, in patients undergoing two consecutive antiviral treatments the percentage of hypothyroidism increased significantly from the first to the second therapeutic schedule in group A (from 4.8% to 19.0%; P

Published
2002

5. Increased serum osteoprotegerin values in long-lived subjects: different effects of inflammation and bone metabolism.

Author

Mazziotti G, Amato G, Sorvillo F, Piscopo M, Rizzo MR, Lalli E, Iride L, Cioffi M, Molinari AM, Paolisso G, and Carella C

Subjects
Adult, Aged, Aged, 80 and over, Biomarkers, Bone Remodeling physiology, Carrier Proteins blood, Cytokines blood, Energy Metabolism physiology, Female, Humans, Male, Membrane Glycoproteins blood, Middle Aged, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B, Aging blood, Bone and Bones metabolism, Glycoproteins blood, Inflammation blood, Receptors, Cytoplasmic and Nuclear blood, Receptors, Tumor Necrosis Factor blood
Abstract

Aim: To evaluate serum osteoprotegerin (OPG) concentrations in relation to age-dependent changes in serum markers of bone metabolism and systemic inflammation., Methods: Two-hundred and eighty-three healthy subjects were evaluated for plasma estimated creatinine clearance (Cr-clearance), C-reactive protein (CRP), bone alkaline phosphatase, C-telopeptides of type-1 collagen (CrossLaps), nuclear factor-kappaB ligand (RANKL) and OPG concentrations., Results: In adult subjects (82 cases aged between 27 and 64 years) serum OPG concentrations were significantly and independently correlated with RANKL and Cr-clearance (R(2): 0.29), but not with CRP and biochemical markers of bone metabolism. In old subjects who were between 65 and 84 years of age (52 cases) serum OPG concentrations were significantly higher as compared with the adult subjects and correlated independently and significantly with serum RANKL, Cr-clearance and CrossLaps values (R(2): 0.63). The highest OPG values were found in the long-lived subjects (149 cases with ages between 85 and 110 years) who also showed increased serum CrossLaps and CRP concentrations as compared with the younger subjects. However, in the long-lived subjects serum OPG concentrations were significantly and independently correlated with Cr-clearance and CRP (R(2): 0.45) but not with CrossLaps values., Conclusions: These data would suggest that different factors might be responsible for the age-dependent enhancement of OPG production. Bone metabolism would seem to be the most important factor influencing serum OPG concentrations in old subjects under 85 years of age, whereas in long-lived subjects the circulating values of this cytokine seem to be mainly correlated with serum CRP which could be a marker of inflammation and cardiovascular risk.

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results